DE69515028D1 - Die hocheffiziente herstellung und isolierung von viruspartikeln - Google Patents

Die hocheffiziente herstellung und isolierung von viruspartikeln

Info

Publication number
DE69515028D1
DE69515028D1 DE69515028T DE69515028T DE69515028D1 DE 69515028 D1 DE69515028 D1 DE 69515028D1 DE 69515028 T DE69515028 T DE 69515028T DE 69515028 T DE69515028 T DE 69515028T DE 69515028 D1 DE69515028 D1 DE 69515028D1
Authority
DE
Germany
Prior art keywords
exchange resin
insulation
cells
highly efficient
virus particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69515028T
Other languages
English (en)
Other versions
DE69515028T2 (de
Inventor
Christopher P Prior
David M Weber
Richard S Gore
James J Harter
Michael E Hrinda
Jonathan J Mitschelen
Thomas W Irish
Pierre M Bay
George C Tarr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Corp
Original Assignee
Immune Response Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp filed Critical Immune Response Corp
Publication of DE69515028D1 publication Critical patent/DE69515028D1/de
Application granted granted Critical
Publication of DE69515028T2 publication Critical patent/DE69515028T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69515028T 1994-03-22 1995-03-22 Die hocheffiziente herstellung und isolierung von viruspartikeln Expired - Fee Related DE69515028T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21583394A 1994-03-22 1994-03-22
PCT/US1995/003668 WO1995025789A1 (en) 1994-03-22 1995-03-22 Highly efficient production and isolation of viral particles

Publications (2)

Publication Number Publication Date
DE69515028D1 true DE69515028D1 (de) 2000-03-16
DE69515028T2 DE69515028T2 (de) 2000-06-29

Family

ID=22804586

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69515028T Expired - Fee Related DE69515028T2 (de) 1994-03-22 1995-03-22 Die hocheffiziente herstellung und isolierung von viruspartikeln

Country Status (12)

Country Link
US (2) US5661023A (de)
EP (1) EP0751988B1 (de)
JP (1) JP3313117B2 (de)
AT (1) ATE189697T1 (de)
AU (1) AU2127395A (de)
CA (1) CA2186034C (de)
DE (1) DE69515028T2 (de)
DK (1) DK0751988T3 (de)
ES (1) ES2141929T3 (de)
GR (1) GR3033268T3 (de)
PT (1) PT751988E (de)
WO (1) WO1995025789A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025789A1 (en) * 1994-03-22 1995-09-28 The Immune Response Corporation Highly efficient production and isolation of viral particles
FR2750433B1 (fr) * 1996-07-01 1998-08-14 Rhone Poulenc Rorer Sa Procede de production d'adenovirus recombinants
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP2325299A3 (de) * 1997-09-05 2011-10-05 Targeted Genetics Corporation Verfahren zur Erzeugung helferfreier Präparate mit hohem Titer aus rekombinanten AAV-Vektoren
JP2002500088A (ja) * 1998-01-12 2002-01-08 ハー マジェスティ イン ライト オブ カナダ アズ リプレゼンティッド バイ ザ ミニスター オブ アグリカルチャー アンド アグリ−フード カナダ 非極性抽出物の単離、回収及び精製方法
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DE10010342A1 (de) * 2000-03-06 2001-09-20 Merck Patent Gmbh Verfahren zur Abreicherung von Endotoxinen
SE0001132D0 (sv) * 2000-03-29 2000-03-29 Cavidi Tech Ab Method of concentrating and recovering a viral enzyme activity from biological samples
WO2001085928A1 (fr) * 2000-05-10 2001-11-15 Mitsubishi Pharma Corporation Procede de preparation de vecteur de virus
US20020177571A1 (en) 2000-11-29 2002-11-28 Gordon Erlinda M. Targeted vectors for cancer immunotherapy
ATE381923T1 (de) * 2001-02-11 2008-01-15 Aquanova Ag Verfahren zur herstellung eines wirkstoffkonzentrats sowie wirkstoffkonzentrat
US20030031626A1 (en) * 2001-07-26 2003-02-13 Thomas Rheinlander Process for the production of pharmaceutical preparations
DE10137515A1 (de) * 2001-07-26 2003-02-13 Diagnostikforschung Inst Verfahren zur Herstellung pharmazeutischer Zubereitungen
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
ES2366617T3 (es) * 2003-04-21 2011-10-21 Epeius Biotechnologies Corporation Métodos y composiciones para el tratamiento de transtornos.
WO2006052302A2 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying adenoviral vectors
DK3192874T3 (da) 2008-06-18 2019-12-16 Oxford Biomedica Ltd Virusoprensning
KR101549296B1 (ko) 2010-04-14 2015-09-01 이엠디 밀리포어 코포레이션 고역가 고순도 바이러스 스톡의 생산 방법 및 이의 사용 방법
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
EP2700399B1 (de) 2011-04-18 2017-05-31 National Center of Neurology and Psychiatry Arzneimittelabgabepartikel und verfahren zu ihrer herstellung
CN104768536B (zh) 2012-09-17 2019-03-29 格雷斯公司 官能化微粒状载体材料和其制备和使用方法
ES2868093T3 (es) 2012-09-17 2021-10-21 Grace W R & Co Medio y dispositivos de cromatografía
EP3094390B1 (de) 2014-01-16 2021-07-07 W.R. Grace & CO. - CONN. Affinitätschromatographiemedien und chromatographievorrichtungen
US11389783B2 (en) 2014-05-02 2022-07-19 W.R. Grace & Co.-Conn. Functionalized support material and methods of making and using functionalized support material
US10695744B2 (en) 2015-06-05 2020-06-30 W. R. Grace & Co.-Conn. Adsorbent biprocessing clarification agents and methods of making and using the same
CN111417713B (zh) * 2017-11-22 2024-04-26 康宁股份有限公司 灌注生物反应器系统及灌注细胞培养方法
US11028124B2 (en) * 2018-05-07 2021-06-08 Repligen Corporation Methods, devices and systems for 3-stage filtration
US20220243224A1 (en) * 2019-04-15 2022-08-04 Children's Hospital Medical Center Viral vector manufacturing methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509070A (en) * 1968-06-13 1970-04-28 American Home Prod Adsorbent for chromatographic purification of virus
US3655509A (en) * 1969-05-29 1972-04-11 Monsanto Co Process for the separation of virus from non-viral proteins
US3925152A (en) * 1971-06-18 1975-12-09 Exploaterings Ab Tbf Virus separation
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6151571A (ja) * 1984-08-21 1986-03-14 Nippon Seibutsu Kagaku Kenkyusho オ−エスキ−病診断用抗原の単離・精製法
AU612383B2 (en) * 1987-06-10 1991-07-11 Immune Response Corporation, Inc., The Prevention and treatment of retroviral disease
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
PT96994B (pt) * 1990-03-09 1998-07-31 Chiron Corp Metodo para purificacao da gp12o de hiv, de forma a proporcionar um glicopeptido
FR2661834B1 (fr) * 1990-05-09 1995-01-27 Merieux Inst Procede de fabrication d'immunogenes de retrovirus et de vaccins contre les infections retrovirales, notamment hiv, et immunogenes et vaccins obtenus.
CA2098510A1 (en) * 1990-12-13 1992-06-14 Kenneth W. Culver Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
WO1995025789A1 (en) * 1994-03-22 1995-09-28 The Immune Response Corporation Highly efficient production and isolation of viral particles
JPH08195877A (ja) * 1995-01-18 1996-07-30 Canon Inc イメージセンサと画像処理回路

Also Published As

Publication number Publication date
EP0751988A1 (de) 1997-01-08
US5661023A (en) 1997-08-26
CA2186034A1 (en) 1995-09-28
EP0751988B1 (de) 2000-02-09
PT751988E (pt) 2000-05-31
GR3033268T3 (en) 2000-09-29
WO1995025789A1 (en) 1995-09-28
DK0751988T3 (da) 2000-06-26
EP0751988A4 (de) 1997-11-12
ES2141929T3 (es) 2000-04-01
AU2127395A (en) 1995-10-09
CA2186034C (en) 2002-11-26
ATE189697T1 (de) 2000-02-15
US6080571A (en) 2000-06-27
JP3313117B2 (ja) 2002-08-12
DE69515028T2 (de) 2000-06-29
JPH10500286A (ja) 1998-01-13

Similar Documents

Publication Publication Date Title
DE69515028D1 (de) Die hocheffiziente herstellung und isolierung von viruspartikeln
EP1394259A3 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
AU7007491A (en) Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
ATE298789T1 (de) Negativstrand rna virus mit selbständiger replikationsaktivität
FI962990A0 (fi) Menetelmä rekombinanttisten adenovirukseen assosioituvien virusten (AAV:iden) valmistamiseksi ja sen käyttöjä
ATE333501T1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps)
DK0923592T3 (da) Fremgangsmåder til rensning af nukleinsyrer
HUP0001271A1 (hu) Eljárás rekombináns adenovírusok előállítására
FR2465508B1 (fr) Membranes poreuses contenant du polyacrylonitrile modifie, pour l'ultrafiltration, procede de preparation de celles-ci et applications desdites membranes
ATE437222T1 (de) Alphavirus replikon-vektorsysteme
ATE452183T1 (de) Eine verbesserte methode zur herstellung und reinigung von adenoviralen vektoren
CA2197683A1 (en) Method for preparing an influenza virus, antigens obtained and applications thereof
FR2756297B1 (fr) Procede de production de virus recombinants
YU78402A (sh) Hemostatički aktivni preparat koji sadrži vwf i postupak njegovog pripremanja
DE68908223T2 (de) Verfahren zur Herstellung von sehr reiner, dichter grossteiliger Kieselsäure.
NO983834D0 (no) En fremgangsmÕte ved rensingen av opasifiserende kontrastmidler
ES2193210T3 (es) Separacion de virus de soluciones de proteinas por ultrafiltracion.
DE69324645T2 (de) Verfahren zur Herstellung von Hepatitis Antigenen und Impfstoffen
ATE133709T1 (de) Peroxidase-gen von mikrobischem ursprung
DE69103798D1 (de) Katalysatorsystem und -verfahren zur selektiven Herstellung von Isoprenyl-Alkylethern aus Isopren.
DK78990A (da) Fremgangsmaade til rensning af ydre membran protein for haemophilus influenza
FR2509630B1 (fr) Procede pour eliminer des impuretes, notamment le potassium, des catalyseurs usages d'argent pour la production d'oxyde d'ethylene
FI98466B (fi) FSME-viruksen läntisen alatyypin eristettyjä DNA- ja RNA-molekyylejä, näitä sisältäviä vektoreita ja soluviljelmiä sekä menetelmä näiden koodittamien peptidien valmistamiseksi
CA2154854A1 (en) Immortalized lymphocytes for production of viral-free proteins
ATE55257T1 (de) Verfahren zur herstellung von hochgereinigten, hepatitis-b-virus-infektionsfreien gammaglobulinen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee